Blue Note Therapeutics

Blue Note Therapeutics is a prescription digital therapeutics (PDT) company focused on developing digital solutions to address mental health challenges faced by cancer patients. Founded with the mission of easing the burden of cancer and improving patient outcomes, Blue Note merges scientific and clinical expertise with neuroscience and digital innovation to create accessible mental health treatments. The company's flagship product, attune, is a prescription digital therapeutic designed to treat anxiety and depression symptoms related to cancer. Attune received Breakthrough Device designation from the US Food and Drug Administration (FDA) in June 2020.

Blue Note's digital therapeutics translate evidence-based, face-to-face cancer-specific therapies into digital formats accessible on patients' mobile devices. These on-demand, self-directed tools allow patients to access mental health support at their convenience. The company's pipeline includes multiple prescription digital therapeutics aimed at reducing anxiety, depression, and other forms of cancer-related distress across the cancer care continuum - from diagnosis through survivorship.

In addition to attune, Blue Note has developed DreAMLand, a prescription-only digital therapeutic to treat anxiety and depressive symptoms in adults with acute myeloid leukemia (AML) who are hospitalized for high-intensity induction chemotherapy. DreAMLand received Breakthrough Device designation from the FDA in January 2022.

Key customers and partnerships

Blue Note Therapeutics has established several key partnerships to expand access to its digital therapeutics. In May 2022, the company partnered with OncoHealth to offer attune through OncoHealth's telehealth platform, Iris. This collaboration enables licensed healthcare professionals to provide attune to cancer patients, expanding access to cancer-specific mental healthcare.

In August 2022, Blue Note partnered with The Oncology Institute (TOI) to make attune available by prescription to eligible TOI patients. This partnership aims to enhance psychological support services for cancer patients in community-based settings. Additionally, in May 2022, Blue Note entered into an exclusive licensing agreement with Bixink Therapeutics for the commercialization of attune and DreAMLand in South Korea, further expanding the company's reach internationally.